Johnson & Johnson will spend more than $14 billion to delve further into the treatment of central nervous system disorders by ... said Friday that drugmaker Sandoz Inc. can start selling a generic ...

while driving Sandoz’s growth in the region in therapeutic areas such as haematology, central nervous system (CNS), and oncology. It has been a considerable growth journey for Stein Holding Group.